Depemokimab reduces exacerbations regardless of baseline asthma control, suggesting uncontrolled symptoms are not necessary ...

GSK will incorporate the findings into messaging that depemokimab patients will adhere to treatment better, ensuring better ...

Arab Finance: GlaxoSmithKline Egypt (GSK–Egypt) recorded EGP 59.123 million in consolidated net profits after tax and non-controlling interest in the first quarter (Q1) of 2025, against EGP 8.99 ...

Big Pharma corporate venture funds may operate in “strategic” or “arm’s length” modes and can be an attractive source of finance which ... Catalyst on the GSK site facilitate these ...

At close: 16 May at 5:42:01 pm GMT+1 Loading Chart for GSK.L ...

As of 12:39:26 p.m. GMT-3. Market Open.

The move comes as GSK faces pressure to replenish its pipeline, with some of its top-selling drugs nearing the end of their ...

With its purchase of Boston Pharmaceuticals' drug, GSK extends a streak of dealmaking it's undertaken to build a liver ...

GSK acquires Boston Pharmaceuticals' efimosfermin for up to $2 billion, targeting liver diseases like MASH and ALD.

GSK GSK2.35%increase; green up pointing triangle will acquire a liver-disease treatment from Boston Pharmaceuticals for up to $2 billion as it seeks to boost its pipeline of new drugs. The British ...

GSK will buy efimosfermin, a liver disease drug in late-stage trials, for up to $2 billion from U.S. biotechnology firm ...